GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Natera Inc (NAS:NTRA) » Definitions » Beneish M-Score

Natera (Natera) Beneish M-Score : -2.95 (As of May. 18, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Natera Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.95 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Natera's Beneish M-Score or its related term are showing as below:

NTRA' s Beneish M-Score Range Over the Past 10 Years
Min: -3.57   Med: -2.64   Max: 2.03
Current: -2.95

During the past 11 years, the highest Beneish M-Score of Natera was 2.03. The lowest was -3.57. And the median was -2.64.


Natera Beneish M-Score Historical Data

The historical data trend for Natera's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natera Beneish M-Score Chart

Natera Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.84 -2.47 -2.46 -2.12 -3.00

Natera Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.72 -2.91 -3.13 -3.00 -2.95

Competitive Comparison of Natera's Beneish M-Score

For the Diagnostics & Research subindustry, Natera's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natera's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Natera's Beneish M-Score falls into.



Natera Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Natera for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8402+0.528 * 0.8403+0.404 * 1.2303+0.892 * 1.3926+0.115 * 0.7813
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8061+4.679 * -0.15435-0.327 * 0.9074
=-2.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $289 Mil.
Revenue was 367.741 + 311.105 + 268.306 + 261.404 = $1,209 Mil.
Gross Profit was 208.601 + 159.858 + 120.995 + 118.255 = $608 Mil.
Total Current Assets was $1,261 Mil.
Total Assets was $1,468 Mil.
Property, Plant and Equipment(Net PPE) was $180 Mil.
Depreciation, Depletion and Amortization(DDA) was $26 Mil.
Selling, General, & Admin. Expense(SGA) was $663 Mil.
Total Current Liabilities was $306 Mil.
Long-Term Debt & Capital Lease Obligation was $347 Mil.
Net Income was -67.599 + -78.031 + -109.03 + -110.803 = $-365 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0 Mil.
Cash Flow from Operations was 27.001 + -58.125 + -29.555 + -78.167 = $-139 Mil.
Total Receivables was $247 Mil.
Revenue was 241.756 + 217.252 + 210.637 + 198.2 = $868 Mil.
Gross Profit was 93.632 + 89.96 + 94.125 + 88.963 = $367 Mil.
Total Current Assets was $1,129 Mil.
Total Assets was $1,319 Mil.
Property, Plant and Equipment(Net PPE) was $170 Mil.
Depreciation, Depletion and Amortization(DDA) was $19 Mil.
Selling, General, & Admin. Expense(SGA) was $591 Mil.
Total Current Liabilities was $291 Mil.
Long-Term Debt & Capital Lease Obligation was $356 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(288.748 / 1208.556) / (246.785 / 867.845)
=0.23892 / 0.284365
=0.8402

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(366.68 / 867.845) / (607.709 / 1208.556)
=0.422518 / 0.502839
=0.8403

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1261.444 + 180.344) / 1468.205) / (1 - (1129.468 + 170.124) / 1318.88)
=0.017993 / 0.014625
=1.2303

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1208.556 / 867.845
=1.3926

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(18.634 / (18.634 + 170.124)) / (26.083 / (26.083 + 180.344))
=0.098719 / 0.126355
=0.7813

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(662.958 / 1208.556) / (590.584 / 867.845)
=0.548554 / 0.680518
=0.8061

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((347.433 + 305.949) / 1468.205) / ((355.827 + 290.969) / 1318.88)
=0.445021 / 0.490413
=0.9074

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-365.463 - 0 - -138.846) / 1468.205
=-0.15435

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Natera has a M-score of -2.95 suggests that the company is unlikely to be a manipulator.


Natera (Natera) Business Description

Traded in Other Exchanges
N/A
Address
13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Executives
Michael Burkes Brophy officer: Chief Financial Officer 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Steven Leonard Chapman officer: Chief Operating Officer 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Daniel Rabinowitz officer: CHIEF LEGAL OFFICER C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN TX 78753
Jonathan Sheena director, officer: Chief Technology Officer C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gail Boxer Marcus director 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Rowan E Chapman director 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Matthew Rabinowitz director, officer: Chief Executive Officer C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Brinkley Ruth Williams director C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Robert Alan Schueren officer: Chief Operating Officer 7400 PASEO PADRE PARKWAY, FREMONT CA 94555
Roelof Botha director C/O SEQUOIA CAPITAL, 2800 SAND HILL RD, SUITE 101, MENLO PARK CA 94025
Herm Rosenman officer: Chief Financial Officer OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Todd C Cozzens director ONE FEDERAL STREET, 25TH FLOOR, BOSTON MA 02110
Monica Bertagnolli director C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Roy D. Baynes director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130